Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Otsuka

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Otsuka's 2012 sales performance.

Otsuka

Pfizer maintains lead in top CNS drug sales - just

Pfizer maintains lead in top CNS drug sales - just Otsuka and Lilly saw the largest decline in CNS drug sales with the Japanese firm dropping an eye-watering 50% compared to 2014, with Lilly falling by 28%. ... Otsuka's anti-psychotic drug Abilify (aripiprazole), which the company co-markets with

Takeda's once-weekly DPP-4 inhibitor cleared in first market

Takeda's once-weekly DPP-4 inhibitor cleared in first market Otsuka has been given a green light to market a new once-monthly formulation of schizophrenia treatment Abilify (aripiprazole) that has been on the market in the US since 2013 and

R&D productivity takes off

R&D productivity takes off Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a

New cancer meds and drug extensions top CHMP recommendations

New cancer meds and drug extensions top CHMP recommendations The CHMP, the drug safety and efficacy arm of the EMA, has recommended approval for Otsuka's Jinarc (tolvaptan) for the treatment of patients with autosomal dominant polycystic kidney disease (ADPKD),

Jinarc backed for European approval in rare kidney disease

Jinarc backed for European approval in rare kidney disease The European Medicines Agency has recommended granting a marketing authorisation to Otsuka's orphan drug Jinarc (tolvaptan). ... The CHMP says that while no cases of liver failure were found in Otsuka's latest trial, it “is possible that in a wider

[ Previous 5 results ] 8 9 10 11 12 13 14 15 16 17 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...